The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 110, Issue 4, 2000, Pages 780-790

  Estlin, E J ^a   Ronghe, M ^a   Burke, G A A ^a   Yule, S M ^b  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Cellular pharmacology; Childhood; Clinical pharmacology; Lymphoblastic leukaemia

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PHARMACOLOGY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; STEROID THERAPY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CELLS; CHILD; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; REMISSION INDUCTION; VINCRISTINE;

EID: 0033753764     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.t01-1-02153.x     Document Type: Review

References (107)

1. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia
2. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukaemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group Study
3. Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA
4. In vitro and in vivo killing of acute lymphoblastic leukaemia cells by L-asparaginase
5. Comparative pharmacokinetic studies of three asparaginase preparations
6. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia
7. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumour response
8. Differences in cerebrospinal fluid penetration of GC: Possible relationship to the prevention of meningeal leukemia
9. Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data
10. Monthly pulses of vincristine and prednisolone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukaemia: A report of the CCG-161 study by the Children's Cancer Study Group
11. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
12. Dexamethasone decreases central nervous system (CNS) relapse and improves event free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL)
13. Differences in the production of L-asparagine in asparaginase-sensitive and resistant lymphoma cells
14. Comparison of the sensitivity of normal haematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo
15. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism
16. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X
17. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12 000 randomised children
18. Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia
19. Continuous infusion cyclophosphamide plus vincristine cytosine-arabinoside and prednisolone for refractory acute lymphoblastic leukaemia in adults
20. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukaemia
21. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia
22. Anthracyclines and anthracenediones
23. Effective dose of L-Asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: A report from the Children's Cancer Study Group
24. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia
25. Clinical evaluation of cyclophosphamide. A new agent for the treatment of children with acute leukaemia
26. Asparaginase (ASNase) induced cytotoxicity depends on the p53 status of the cells
27. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia
28. Glucocorticosteroid therapy in childhood acute lymphoblasttc leukaemia
29. The use of glucocorticoids in acute lymphoblastic leukaemia of childhood. Molecular, cellular, and clinical considerations
30. Association of delivered drug dose and outcome for children with acute lymphoblastic leukaemia and unfavourable presenting features
31. Improved therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features: A follow up report of the Children's Cancer Group Study CCG-106
32. Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression
33. Vincristine pharmacokinetics after repetitive dosing in children
34. Vincristine disposition in children with acute lymphoblastic leukaemia
35. Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity
36. Vincristine in the treatment of acute leukaemia in children
37. Monitoring glucocorticoid therapy: A pharmacokinetic approach
38. Clinical study of daunomycin (NSC 82151) in children with acute leukaemia
39. Relationships between tumour responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumour xenografts
40. Amino acid control of asparagine synthetase: Relation to asparaginase resistance in human leukaemia cells
41. Prednisolone therapy of acute lymphatic leukemia in children
42. Prednisolone in childhood leukemia. Comparison of interrupted with continuous therapy
43. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
44. Antitumor promotion and anti-inflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone
45. The role of vincristine in the treatment of childhood acute leukaemia
46. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
47. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
48. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs
49. High glucocorticoid receptor content of leukemic blasts is a favourable prognostic factor in childhood acute lymphoblastic leukemia
50. Biochemical characterization of U937 cells resistant to L-asparaginase: The role of asparagine synthase
51. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia
52. Relationship between tumour cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: Mechanism of inoculum effects
53. Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukaemia cells
54. Cellular pharmacokinetics of daunorubicin: Relationships with the response to treatment in patients with acute myeloid leukaemia
55. Varying prednisolone dosage in remission induction of previously untreated childhood leukemia
56. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumours
57. Use of L-asparaginase in childhood ALL
58. Results of treatment of advanced stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and co-ordinated high-dose methotrexate and cytarabine
59. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukaemia and unfavourable presenting features: A report from the Children's Cancer Group
60. Augmented post-induction therapy for children with high risk acute lymphoblastic leukaemia and a slow response to initial therapy
61. Apoptosis induced by antimetabolites, taxanes or asparaginases in vitro depends on the p53 status of the leukaemic cells
62. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukaemia: The Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols
63. Characterisation of a glucocorticoid-sensitive human lymphoid cell line
64. Relationship between DNA cross-links, cell cycle and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard
65. The importance of L-asparaginase (A'ase) in the treatment of acute lymphoblastic leukemia (ALL) in children: Results of the EORTC 58881 randomized phase III trial showing greater efficiency of E. coli (E. coli) as compared to Erwinia (Erw) A'ase
66. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leuukaemia
67. Relation between age immunophenotype and in vitro drug resistance in 396 children with acute lymphoblastic leukemia - Implications for treatment of infants
68. Continuous vincristine infusion as part of a high dose chemotherapy regimen: Drug kinetics and toxicity
69. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas
70. Response of recurrent acute lymphoblastic leukemia to GC: Serial studies of receptor content, in vivo cytokinetic changes and clinical responses
71. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: A pediatric oncology group study
72. The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas
73. L-Asparaginase (L-ASP) in advanced childhood leukemia: Comparative trial of drug schedules singly and in combination
74. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukaemia treated on two consecutive trials of the Children's Cancer Group
75. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukaemia patients: A Children's Cancer Group Report
76. Chemotherapy in 998 unselected childhood acute lymphoblastic leukaemia patients. Results and conclusions of the multi-centre trial ALL-BFM 86
77. Pharmacokinetics of dexamethasone in children
78. Antimicrotubule agents
79. L-Asparaginase activity in plasma and other biological fluids
80. The comparative effects of selected cytotoxic agents on transplanted haematopoietic cells
81. Ifosfamide in paediatric oncology: Tried but not tested
82. Induction toxicity in childhood acute lymphoblastic leukaemia: A comparison of two schedules of daunorubicin administration
83. Pre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity
84. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukaemic T-lymphocytes
85. Intermittent continuous IV infusion of high-dose cyclophosphamide for remission induction in acute leukaemia
86. Anthracycline dose in childhood acute lymphoblastic leukaemia: Issues of early survival versus late cardiotoxicity
87. Leukaemic cell and plasma daunomycin concentrations after bolus and 72 hour infusion
88. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukaemia patients
89. Functional interactions between Stat5 and the glucocorticoid receptor
90. Cyclophosphamide in the treatment of common neoplastic diseases of childhood
91. E. coli L-asparaginase in the treatment of leukemia and solid tumours in 131 children
92. Daunomycin, an antitumour antibiotic, in the treatment of neoplastic disease
93. Influence of schedule of alkylating agent cytotoxicity in vitro and in vivo
94. Apoptosis and steroid hormones
95. Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis
96. Leukemia after therapy with alkylating agents for childhood cancer
97. Cell cycle arrest and apoptosis of leukaemia cells induced by L-asparaginase
98. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukaemia: Results of protocol ALL VI form the Dutch Childhood Leukaemia Study Group
99. Pharmacokinetics of 'activated' cyclophosphamide and therapeutic efficacies
100. Modified pharmacokinetics of L-asparaginase from E. coli by formation of specific antibodies to L-asparaginase of different immunoglobulin classes in children with acute lymphoblastic leukaemia
101. Prednisolone therapy of acute childhood leukemia: Prognosis and duration of response in 330 treated patients
102. Anti-asparaginase (ASP) antibodies do not impact event-free survival (EFS) in children with acute lymphoblastic leukaemia (ALL)
103. Induction of apoptosis by anti-cancer drugs with disparate modes of action: Kinetics of cell death and changes in c-myc expression
104. Cyclophosphamide metabolism in children
105. Cyclophosphamide pharmacokinetics in children
106. Alkylating agent resistance in paediatric oncology